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Serum metabolomics profiles 
in response to n-3 fatty acids 
in Chinese patients with type 
2 diabetes: a double-blind 
randomised controlled trial
Ju-Sheng Zheng1,2,*, Mei Lin3,*, Fumiaki Imamura2, Wenwen Cai1, Ling Wang4, Jue-Ping Feng3, 
Yue Ruan5,6, Jun Tang1, Fenglei Wang1, Hong Yang3 & Duo Li1
We aimed to investigate the change of serum metabolomics in response to n-3 fatty acid supplements 
in Chinese patients with type 2 diabetes (T2D). In a double-blind parallel randomised controlled trial, 
59 Chinese T2D patients were randomised to receive either fish oil (FO), flaxseed oil (FSO) or corn 
oil capsules (CO, served as a control group) and followed up for 180 days. An additional 17 healthy 
non-T2D participants were recruited at baseline for cross-sectional comparison between cases and 
non-cases. A total of 296 serum metabolites were measured among healthy controls and T2D patients 
before and after the intervention. Serum 3-carboxy-4-methyl-5-propyl-2-furanpropanoate (CMPF) (P-
interaction = 1.8 × 10−7) was the most significant metabolite identified by repeated-measures ANOVA, 
followed by eicosapentaenoate (P-interaction = 4.6 × 10−6), 1-eicosapentaenoylglycerophosphocholine 
(P-interaction = 3.4 × 10−4), docosahexaenoate (P-interaction = 0.001), linolenate (n-3 or n-6, P-
interaction = 0.005) and docosapentaenoate (n-3, P-interaction = 0.021). CMPF level was lower in T2D 
patients than in the healthy controls (P = 0.014) and it was significantly increased in the FO compared 
with CO group (P = 1.17 × 10−7). Furthermore, change of CMPF during the intervention was negatively 
correlated with change of serum triglycerides (P = 0.016). In conclusion, furan fatty acid metabolite 
CMPF was the strongest biomarker of fish oil intake. The association of CMPF with metabolic markers 
warrants further investigation.
Type 2 diabetes (T2D) is characterized by insulin resistance and impaired β -cell function. These manifestations 
involve complex biological pathways, partly evidenced by metabolomics studies1–3. Amino acids, sugar metabo-
lites and choline-containing phospholipids have been identified to be of potential importance in the pathogenesis 
of T2D4–7, in addition to traditional biomarkers, such as fasting glucose and adiponectin.
The human metabolome contains a huge number of molecules derived from diet. Thus, metabolomics is a 
promising approach to explain pathophysiological roles of dietary components. Long-chain n-3 polyunsaturated 
fatty acids (PUFA) are of interest topic, because of inconsistent findings in literature. Animal studies have pro-
vided convincing evidence that n-3 PUFA improve glucose metabolism8,9, with a variety of potential mechanisms 
including improved membrane fluidity8, anti-inflammatory effect10, and genetic regulation11. Despite the biolog-
ical plausibility, studies in humans have yielded conflicting results. Meta-analyses based on observational studies 
show that dietary intakes of long-chain n-3 PUFA are inversely associated with T2D risk in Asian populations, but 
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positively associated with the risk in Western populations12,13. Randomised controlled trials indicate no signifi-
cant effect of long-chain n-3 PUFA on glucose-insulin homeostasis14,15, although n-3 PUFA substantially reduce 
blood concentrations of triglycerides (TG), one of risk factors for T2D and cardiovascular diseases16,17. To explain 
the conflict between mechanistic studies and human studies and to better understand how n-3 PUFA might 
influence the pathogenesis of T2D, metabolomics profiles in response to n-3 PUFA intervention in T2D patients 
are warranted.
We conducted a multi-centre double-blind parallel randomised controlled trial (n = 185) to investigated the 
effects of n-3 PUFA supplements (both marine [fish oil] and plant source [flaxseed oil]) on glycaemic traits in 
Chinese patients with T2D. This trial found that fish oil supplement, compared with corn oil control group, 
significantly decreased glycated hemoglobin (HbA1c) and TG18. In the present study, using serum metabolom-
ics data (n = 53) from a single centre of the aforementioned multi-centre trial (Fig. 1), our primary aim was to 
examine change of serum metabolomics in response to n-3 fatty acid supplements in Chinese T2D patients; and 
the secondary aims were to conduct a case-control comparison for serum metabolomics between T2D cases and 
non-cases, and to examine the correlation of the serum metabolites with metabolic markers among T2D cases 
and non-cases.
Results
Characteristics of the study population and compliance of the participants. Among the three 
intervention groups, no significant difference in anthropometric or biochemical parameters was observed at base-
line (Table 1). However, FO group showed fewer women participants, lower BMI, TG and HDL-C than CO group. 
The healthy controls, compared with T2D patients in the trial, had significantly lower BMI, systolic and diastolic 
blood pressure, LDL-C and fasting glucose, and higher HDL-C concentration (P < 0.05) (Table 1). Changes of 
blood metabolic markers were presented in the Supplemental file (Supplemental file 1: Supplemental Table 1).
As a test of compliance to the intervention, erythrocyte eicosapentaenoic acid (EPA, C20:5n3) and doco-
sahexaenoic acid (DHA, C22:6n3) significantly increased from 0.59% (standard error [SE] = 0.05) and 4.86% 
(SE = 0.26) to 1.65% (SE = 0.32) and 6.55% (SE = 0.34) respectively in the fish oil (FO) arm, compared with the 
change from 0.44 (SE = 0.04) to 0.41 (SE = 0.03) in the corn oil (CO) arm (P = 0.035 for EPA, P = 0.001 for DHA). 
Erythrocyte alpha-linolenate (ALA, C18:3n3) levels were increased in the FSO arm, but not significantly different 
from change in the CO arm (P = 0.13).
Change of serum metabolites in response to n-3 PUFA intervention. Results of pattern recognition 
analyses: principal component analysis (PCA) and partial least square-discriminant analysis (PLS-DA). For PCA, 
five principal components were derived, as linear combinations of changes in metabolites: the number of compo-
nents was based on scree plot and the five components explained 35% of total variability of metabolites’ changes. 
The first principal component was significantly different between the FSO arm and the CO arm (P = 0.006). No 
significant difference between different groups was observed for the other components. Of 296 metabolites, 30 
metabolites, the most contributing to the first principal component, were selected for visualization (Supplemental 
file 1: Supplemental Figure 1), including fatty acid species and derivatives with various chain lengths such as 
palmitate, linoleate, acyl-carnitines, and hydroxyl fatty acids. For PLS-DA, we found that all of the top three 
components could significantly (P < 0.05) separate FO and FSO group from CO group (Supplemental file 1: 
Supplemental Table 2). With ranking by the variable importance in projection (VIP) score, 3-carboxy-4-methyl-
5-propyl-2-furanpropanoate (CMPF) was the top metabolite identified for the component distinguishing the 
FO and CO groups, followed by PC-EPA (1-eicosapentaenoylglycerophosphocholine) and EPA (Supplemental 
Figure 1. Design of the present study. 
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file 1: Supplemental Figure 2A). For the distinction between FSO and CO groups, indolepropinate, erucate and 
mannitol were the top three metabolites identified by the ranking (Supplemental file 1: Supplemental Figure 2B).
Results from repeated-measures ANOVA. Changes of six metabolites were significantly different between trial 
arms (Table 2). CMPF showed the lowest P-value of 1.8 × 10−7 for interaction of time and groups, followed by 
serum EPA (P = 4.6 × 10−6), PC-EPA (P = 3.4 × 10−4), DHA (P = 0.001), linolenate (C18:3n-3 or n-6, P = 0.005) 
and n-3 DPA (docosapentaenoate, C22:5n-3) (P = 0.021). In post hoc analysis comparing between FO and CO 
groups, FO group showed significant increases in concentrations of CMPF (P = 1.17 × 10−7 for time × group 
interaction), EPA (P = 5.81 × 10−6), PC-EPA (P = 8.21 × 10−5), DHA (P = 1.79 × 10−4) and DPA (P = 8.27 × 10−4), 
while the CO group showed trends toward declines of these PUFA’ concentrations. For the comparison between 
FSO and CO groups, linolenate (P = 7.75 × 10−6), n-3 DPA (P = 3.57 × 10−4), EPA (P = 4.68 × 10−4) and PC-EPA 
(P = 0.008) showed significant time × group interaction.
Trial participants with diabetes
Pgroup*
Healthy control 
(n = 17) Pcase-controls*
Fish oil 
(n = 18)
Flaxseed oil 
(n = 18)
Corn oil 
(n = 17)
Age, y 63.6 ± 6.13 62.8 ± 12.6 63.4 ± 8.87 0.94 59.8 ± 9.2 0.13
Female, n 9 14 13 0.15 10 0.56
Weight, kg 66.8 ± 11.3 64.5 ± 13.8 65.2 ± 12.8 0.65 58 ± 7.56 0.037
BMI 25.3 ± 3.32 25.3 ± 4.76 26.1 ± 3.9 0.95 21.8 ± 1.84 < 0.001
SBP, mmHg 141.7 ± 23.6 140.1 ± 15.6 135.3 ± 22.1 0.19 113.5 ± 12.7 < 0.001
DBP, mmHg 79.4 ± 10.5 80.1 ± 10.2 76.4 ± 10.1 0.12 67.9 ± 6.68 < 0.001
Heart rate, bpm, 72.0 ± 10.8 72.1 ± 10.2 72.8 ± 14.4 0.84 71.5 ± 7.30 0.93
HDL-C, mmol/L 0.96 ± 0.24 1.11 ± 0.29 1.09 ± 0.18 0.09 1.45 ± 0.32 < 0.001
LDL-C, mmol/L 3.02 ± 0.90 2.95 ± 0.72 3.01 ± 1.12 0.72 2.61± 0.56 0.038
TC, mmol/L 4.57 ± 0.94 4.53 ± 0.71 4.76 ± 1.05 0.37 4.97 ± 0.80 0.25
TG, mmol/L 1.53 ± 0.82 1.43 ± 0.73 1.90 ± 1.08 0.70 1.16 ± 0.47 0.06
Fasting glucose, mmol/L 8.05 ± 3.48 7.27 ± 2.63 6.92 ± 2.56 0.48 4.64 ± 0.52 < 0.001
Table 1.  Characteristics of the participants included in the metabolomics analyses. Abbreviation: SBP, 
systolic blood pressure; DBP, diastolic blood pressure; HDL-C, high-density lipoprotein cholesterol; LDL-C, 
low-density lipoprotein cholesterol; TC, total cholesterol; TG, triglycerides. Values are expressed as mean  ±  SD.  
* Pgroup is for differences between the groups of the trial and Pcase-controls is for differences between trial participants 
and healthy controls, evaluated by analysis-of-variance for continuous variables or Fisher’s exact test for sex 
proportion.
Metabolites Time
Fish oil 
(n = 18)
Flaxseed oil 
(n = 18)
Corn oil 
(n = 17) Ptime Pgroup Ptime×group
CMPF
Baseline 1.30 ± 0.27 0.79 ± 0.16 0.76 ± 0.16 1.7 × 10−6 2.12 × 10−8 1.8 × 10−7 †
Endpoint 5.57 ± 0.60 1.33 ± 0.30 1.11 ± 0.23
EPA
Baseline 1.07 ± 0.08 0.73 ± 0.10 0.97 ± 0.06 2.0 × 10−6 4.5 × 10−4 4.6 × 10−6 †,‡
Endpoint 3.05 ± 0.40 0.87 ± 0.09 0.73 ± 0.07
PC-EPA
Baseline 0.93 ± 0.10 0.64 ± 0.09 0.83 ± 0.10 1.5 × 10−4 1.7 × 10−4 3.4 × 10−4 †,‡
Endpoint 3.44 ± 0.57 1.09 ± 0.14 0.74 ± 0.10
DHA
Baseline 1.01 ± 0.06 0.88 ± 0.08 0.97 ± 0.08 0.010 0.105 0.001†
Endpoint 1.55 ± 0.14 0.86 ± 0.08 0.83 ± 0.07
Linolenate (n-3 or n-6)
Baseline 1.18 ± 0.10 1.00 ± 0.08 1.37 ± 0.11 0.940 0.015 0.005‡
Endpoint 0.96 ± 0.09 1.16 ± 0.11 0.93 ± 0.79
DPA (n-3)
Baseline 1.14 ± 0.10 0.91 ± 0.10 1.39 ± 0.13 0.758 0.551 0.021†,‡
Endpoint 1.38 ± 0.17 0.94 ± 0.10 0.90 ± 0.10
Table 2.  Relative concentrations of selected metabolites among Chinese adults with type 2 diabetes in 
Wuhan, China: a clinical trial of fish oil and flaxseed oil*. * Data are expressed are mean ± SE. P values were 
based on ANOVA evaluating the three groups and two time points. The metabolites were selected from 296 
metabolites. Only these six factors were statistically significant for differences in changes during follow-up, 
with P values < 0.05 after correction for false-discovery rate for multiple comparisons between three groups. 
†Five metabolites showed significant differences in changes between fish oil group and corn oil group. ‡Four 
metabolites in this table showed significant differences in changes between flaxseed oil group and corn oil 
group. Abbreviation: CMPF, 3-carboxy-4-methyl-5-propyl-2-furanpropanoate; EPA, eicosapentaenoate; PC-
EPA, 1-eicosapentaenoylglycerophosphocholine; DHA, docosahexaenoate; DPA, docosapentaenoate.
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Metabolomics profiles of T2D patients and healthy controls. Of the 296 metabolites, 151 were sig-
nificantly different between T2D patients and healthy controls at baseline after adjustment for age, sex and BMI 
and correction for multiple testing, among which 99 were lower in T2D patients than in healthy controls and 52 
higher (Supplemental file 1: Supplemental Table 3, Supplemental Figure 3). We found that CMPF (P = 0.014), 
PC-EPA (P = 5.49 × 10−6), EPA (P = 2.45 × 10−7) and DHA (P = 4.22 × 10−7) in T2D patients at baseline was 
significantly lower than in healthy controls (Supplemental file 1: Supplemental Figure 4).
Correlation of furan fatty acid metabolite CMPF with serum n-3 fatty acids and metabolic 
traits. In the analysis of correlations between metabolites in those with or without diabetes together at 
baseline, CMPF showed positive association with serum EPA (r = 0.27, P = 0.031, adjusted for age, sex, BMI, 
and diabetes status) and DHA (r = 0.31, P = 0.013), but not with other metabolic markers. In analysis among 
T2D patients in the trial, the change of CMPF was correlated with those of serum EPA (r = 0.62, P < 0.001) 
and DHA (r = 0.57, P < 0.001) (Fig. 2); and not significantly correlated with any other examined metabolic risk 
factor, except for TG (r = − 0.35, P = 0.016) (Fig. 2). This inverse correlation between changes of CMPF and TG 
remained significant with further adjustment for the change of serum EPA and DHA (r = − 0.31, P = 0.039).
Discussion
To the best of our knowledge, this was the first study to investigate the metabolomics change in response to 
randomised controlled interventions of plant-based and marine-based n-3 PUFA in Chinese T2D patients. 
Pattern-recognition approach showed that both the plant-based and marine-based PUFA interventions led to 
significant changes in metabolite patterns related to medium-chain and long-chain fatty acids. We found that the 
concentration of CMPF the most significantly increased in response to the intervention of marine-based PUFA. 
In the case-control comparison at baseline, CMPF was substantially higher in the healthy controls than in the 
T2D patients. Furthermore, change of CMPF during the intervention was negatively correlated with change of 
serum TG, which appeared to be independent of change of serum n-3 PUFA.
CMPF has been studied for its potential adverse effect on glucose metabolism. CMPF is a major endogenous 
metabolite of furan fatty acids in human, and it mainly derived from fish consumption or potentially from oxi-
dation of unsaturated fatty acids19–21. In a recent study, CMPF was found to be elevated in the plasma of patients 
with gestational diabetes, impaired glucose-tolerance or T2D22. In addition, a rodent experiment demonstrated 
that CMPF could directly affect β -cell function, impair mitochondrial function, decrease glucose-induced ATP 
accumulation and induce oxidative stress22. In addition, plasma CMPF concentration in 106 non-diabetic Finnish 
Figure 2. Correlation between changes of CMPF with changes of serum EPA, DHA and TG during the 
intervention. P-values were adjusted for age, sex, BMI and trial arms. The inverse correlation between changes of 
CMPF and TG remained significant with further adjustment for the change of serum EPA and DHA (r = − 0.31, 
 P = 0.039). EPA, eicosapentaenoate; DHA, docosahexaenoate. TG, triglycerides; CMPF, 3-carboxy-4-methyl-5-
propyl-2-furanpropanoate.
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participants of a recent randomised trial was much lower than diabetic patients23. Because of the potential adverse 
effect of CMPF on diabetes outcomes, higher levels of CMPF in T2D patients than in healthy controls would be 
expected. However, opposite result was observed in the present study in China.
Given that circulating CMPF was a potential biomarker of fish oil supplements and that circulating marine 
n-3 PUFA and CMPF were high correlated, it was reasonable to postulate that the association of CMPF with 
metabolic markers may be similar as to that of marine n-3 PUFA. In line with this postulation, available evidence 
suggested that the inconsistent findings for the associations of CMPF with glycaemic traits and T2D status were 
similar to prior findings for marine n-3 PUFA. For example, Prentice et al.2 reported that plasma marine n-3 
PUFA concentration was higher in diabetic patients compared with the controls. In contrast, our previous work in 
China showed that marine n-3 PUFA was lower in T2D patients compared with controls24. Inconsistency related 
to n-3 PUFA between Western and Asian populations was observed in prospective cohort studies: consumption 
of marine n-3 PUFA was inversely associated with T2D risk in Asian populations, but not in the Western pop-
ulations13,25. Because sample sizes in the present study and the previous investigations on CMPF were small22,23, 
a study with a larger sample size both in Asian and Western populations is needed to further explore the role of 
CMPF in the etiology of T2D. In addition, detailed relationship of CMPF with n-3 PUFA metabolism is not clear 
at this stage and warrant further investigation.
Circulating CMPF was elevated after fish or fish oil consumption, as shown in the present study and previous 
trials20,23,26, possibly reflecting that EPA and furan fatty acid, precursors of CMPF20, were present in fish or fish oil. 
One interesting finding in this study was that CMPF was identified as the strongest correlate with fish oil inter-
vention. Moreover, we found that increased serum CMPF was significantly associated with decreased serum TG, 
an important risk factor for diabetes and cardiovascular diseases. In contrast, increased serum concentration of 
CMPF was not significantly correlated with any glycaemic parameters in the present study, which was consistent 
with trials of fish oil supplements14,27. Therefore, the overall association of CMPF with glycaemic traits was not 
clear, and study with larger sample size is needed for replication. Another point of concern is that CMPF is con-
sidered as a protein-bound uremic toxin, which is elevated in patients with chronic kidney disease and demon-
strated to be detrimental for renal function28,29. Therefore, at least with foci on cardiovascular health, diabetes, 
and kidney function, future research on CMPF is necessary. Future research on CMPF should evaluate its effects 
on different tissues and physiological functions.
We did not observe significant difference in change for the erythrocyte ALA composition between FSO and 
CO groups; however, we found that the metabolites’ pattern characterized by PCA distinguished FSO and CO 
group as visualized partly with a cluster tree of 30 metabolites. Most of these 30 metabolites were fatty acids and 
derivatives, which indicated that an FSO supplement may remarkably change multiple fatty acid metabolites. The 
possible mechanism is that various PUFA in FSO influence fatty acid metabolism in the liver rather than individ-
ual fatty acids, for example suppressing fatty acid synthesis and further triglycerides synthesis30. This observation 
highlights needs for further investigation.
Major limitations of the present study are the small sample size, the number of statistical tests that might 
include false-positive findings and that more than half of the patients were taking statin, which may influence 
lipid metabolism. Apparently, replication in independent populations is needed. Yet it is the first study to investi-
gate the metabolomics response to plant-based and marine-based n-3 PUFA in T2D patients with the randomised 
controlled design and to provide novel information on CMPF. Another limitation is that the available metabolites 
examined in the study are still insufficient to fully understand the effects of n-3 PUFA supplements on lipid and 
glucose metabolism. Furthermore, the compliance to the intervention and to fasting hours may vary among 
different groups, although erythrocyte fatty acid composition measurement before and after the trial has some 
suggestions for the compliance. Last, the baseline characteristics (such as sex, BMI, TG, HDL-C) among different 
trial arms may different from each other, although no significant difference was detected (due to small sample 
size). The potential unbalanced baseline features was consistent with that of serum metabolite linolenate among 
the three trial arms, which was much lower in FSO group compared with the other groups. These unbalanced 
baseline characteristics may potentially bias the results of the present study.
In conclusion, the present study suggested that serum furan fatty acid metabolite CMPF was the strongest 
biomarker of fish oil intake, and change of serum CMPF was negatively correlated with change of serum TG in 
Chinese T2D patients. These finding could potentially spark interest among scientists to further investigate the 
role of CMPF in the n-3 PUFA-T2D association, as well as its role in lipid metabolism and non-communicable 
diseases.
Methods
Participants and study design. The current study evaluated metabolomics data from 53 adults with dia-
betes who participated in Wuhan, China, one of sites of a multi-centre trial in China; and 17 controls without 
diabetes who underwent health examination. The trial protocol was registered and available at ClinicalTrials.gov 
(No. NCT01857167) on May 10, 2013. The study was approved by the Ethics Committee of College of Biosystem 
Engineering and Food Science at Zhejiang University (No. 2013011). All the participants gave written informed 
consent. The study methods and reporting were carried out in accordance with the CONSORT 2010 guidelines.
The primary aim of the multi-centre randomised controlled trial was to investigate the effect of n-3 PUFA 
suppelments on glycaemic traits in Chinese T2D patients. The trial screened 252 potentially-eligible adults with 
known T2D status in three study centres from June 2013 to June 2014 and recruited 185 T2D cases: Wuhan 
(Central China) (n = 59, assessed for metabolomics), Changshan (Southeast China) (n = 47) and Lanzhou 
(Western China) (n = 79). The total sample size was calculated based on 80% power (α two-tailed = 0.05) to detect 
difference in homeostasis model assessment for insulin resistance (HOMA-IR) by 20% or 0.63 (SD = 1.1) between 
groups, with consideration of 20% drop-out rate (n = 187, 62/group), based on our previous work31. The inclu-
sion criteria were (1) fasting blood glucose > 7.0 mmol/L or on use of diabetic medications; (2) between 35 and 
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80 years old for men and between post-menopausal and 80 years old for women. The exclusion criteria were (1) 
having familial hypertriglyceridemia or with blood TG concentrations > 4.56 mmol/L; (2) a history of hepatic or 
kidney disease, or any type of cancer; (3) participation in another clinical trial within 30 days prior to screening.
After screening, participants were randomly assigned to one of the three groups by computer-generated ran-
dom numbers with a block size of six: fish oil (FO, 4 capsules/day, 50% of EPA and DHA), flaxseed oil (FSO, 
4 capsules/day, 63% of ALA) and corn oil (CO, 4 capsules/day, served as a control within this trial). Allocation 
sequence was generated by Ju-Sheng Zheng, and doctors/nurses at each study center enrolled and assigned par-
ticipants to the intervention groups. The dosage levels of n-3 PUFA were consistent with those used in previ-
ous trials32. The duration of intervention was 180 days. All the participants were given four bottles of capsules 
(90 capsules/bottle) for 90-day intervention at baseline and the mid-point of the intervention (90 days). Types 
of capsules were concealed. At visit of 90 days and the end-point of intervention, participants underwent on-site 
examination.
In the present study based on a single centre in Wuhan, China (n = 59), participants were randomly allocated 
to FO (n = 20), FSO (n = 20) and CO group (n = 19). Three participants (two in FO group and one in CO group) 
dropped out of the trial. Among the remaining 56 participants, serum samples of 53 participants were assayed 
for metabolomics profiling (Fig. 1). Compliance to the intervention was assessed by repeated measurements of 
erythrocyte membrane phospholipid n-3 fatty acid compositions. Among the 53 participants, 29 of them were 
taking statins.
In the single centre, a case-control study was simultaneously conducted to compare the metabolomics profiles 
between T2D cases and non-cases. Seventeen healthy controls were recruited through a health-check program 
undertaken in the same period as the trial ran. They were not invited to the trial and were informed of the aim 
of the observational study. The inclusion and exclusion criteria were the same as the criteria applied to the above 
trial, except for the T2D case status.
Experiment oil capsule preparation. We standardized each of fish oil (FO), flaxseed oil (FSO) or corn 
oil (CO) capsules to one gram with identical appearance. Each FO capsule provided 500mg of EPA + DHA (EPA: 
DHA = 3:2), and other major fatty acids in each FO capsule were C16:0 (71.4 mg), C18:1n-9 (58.4 mg), C16:1 
(56 mg), C20:0 (39.4 mg) and C14:0 (34.6 mg). Each FSO capsule contain 630 mg of ALA, 155 mg of C18:2n-6 
and 137 mg of C18:1n-9. Major fatty acids in each CO capsule were C18:2n-6 (534 mg), C18:1n-9 (299 mg) and 
C16:0 (121 mg). All the capsules were made in the Neptunus Bioengineering Co., Ltd (Hangzhou, China). All the 
capsules were kept in white bottles (90 capsules/bottle), which were labeled as Oil A, Oil B and Oil C for the three 
types of capsules. None of the participants or the nurses/physicians in the study centers knew the oil types during 
the intervention.
Serum metabolomics measurement. Venous blood samples were collected from participants 
in this trial and case-control study (n = 76 in total) after an overnight fasting (> 8 h): for trial participant, 
follow-up samples were also collected. Sera were shipped on dry ice to Zhejiang University, Hangzhou, 
China, for storage at − 80 °C. Then, 500 μ l of sera were shipped to Metabolon’s Shanghai Jiao Tong University 
Laboratory (Shanghai, China) for metabolomics assays with an non-targeted gas-chromatography- and liquid 
chromatography-mass-spectrometry33,34. This method identified 407 signals confirmed with molecular mass 
detected with either positive or negative ion mode, including CMPF, phospholipid species, and fatty acid acyl 
chains of DHA, EPA, and other fatty acids. Single molecules or fragments were evaluated as individual metab-
olites, expressed as relative strengths of signals across study participants (trial participants and controls). The 
details of the assays and quality-control analyses, conducted by Metabolon, Inc. (Durham, North Carolina), are 
presented in the Supplemental file 2.
Measurement of anthropometric and blood biochemical parameters. Heart rate, blood pressure 
and anthropometric parameters, including weight, height, waist and hip circumference, were measured by trained 
staff at baseline, 90 days and 180 days of the intervention. Serum biochemical parameters were assessed at the 
baseline and endpoint of the trial with samples randomly distributed over assays, where assessors were blinded for 
types of oils. High-density lipoprotein cholesterol (HDL-C), low-density lipoprotein cholesterol (LDL-C), total 
cholesterol, TG and glucose levels were measured by commercially available kits on HITACHI 7020 chemistry 
analyzer. Serum insulin was measured by commercially available reagent kit. Using fasting glucose and insulin, 
HOMA-IR was calculated by using the formula: glucose (mmol/L) × insulin (mIU/L)/22.5. Erythrocyte mem-
brane phospholipid fatty acids were measured by gas chromatography, as previously described35 and expressed as 
% of a total of erythrocyte membrane phospholipid fatty acids.
Statistical analysis. Descriptive statistics included crude comparison in demographic factors and metabolic 
risk factors between the trial arms and between T2D cases and controls. Also, a treatment effect on each meta-
bolic risk factor was evaluated by repeated-measures ANOVA. Values for each metabolite were log transformed. 
Metabolites with more than 20% of missing values were excluded from the analysis (111 metabolites). Results 
from 296 metabolites were available for the analyses. Missing values for metabolites included were assumed to be 
below the detection limit and imputed with half the observed minimum values.
To investigate changes in metabolomics profiles by interventions, we first calculated the changes of 296 metab-
olites and took pattern recognition approach of the changes. We conducted PCA for the changes. We examined 
whether each principal-component scale could separate three intervention arms by running linear regression 
with adjustment for age, sex and BMI, and then examined which metabolites contributed to the principal com-
ponent separating the intervention arms. We also conducted PLS-DA, as a supervised method, to determine 
what metabolites’ changes jointly identified the different intervention arms36. In the PLS-DA, we ranked the 
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metabolites based on the VIP scores from the first component generated by PLS-DA, as used previously37. Based 
on PCA and PLS-DA, metabolites responding to intervention were characterized.
A change of each metabolite over time was tested by repeated-measures ANOVA in which treatment effects 
were tested by time × group interaction term. A significant difference was based on a P value (α = 0.05) adjusted 
for multiple testing for 296 signals by using false-discovery rate correction often referred to as q-values38. If a 
significant difference was indicated, pair-wise comparisons between two groups were similarly performed with 
repeated-measures ANOVA with α = 0.05/3 = 0.017.
Comparison between T2D patients (trial participants) and healthy controls might have confounding. Thus we 
used multivariable-adjusted linear regression for each of 296 signals, including a metabolite as an independent 
variable, and case-control status as a dependent variable, with false-discovery-rate correction for multiple testing. 
To obtain stable estimates with the limited sample size (53 cases/17 controls), we only modelled age, sex and BMI 
as covariates.
We additionally examined partial correlation coefficients between changes of CMPF, a known chemical present 
in fish and potentially related to metabolic risk22,23,26, and changes of the serum n-3 fatty acids and conventional 
metabolic markers, with adjustment for age, sex, and BMI. Similarly, partial correlation coefficients were also 
examined cross-sectionally in all participants (healthy controls and baseline measures of the trial participants), 
with adjustment for age, sex, BMI and disease status.
Statistical analyses for the metabolomics data were conducted by using MetaboAnalyst 3.0, an online compre-
hensive tool suite for metabolomics data analysis39–41 (http://www.metaboanalyst.ca/MetaboAnalyst/faces/home.
xhtml). The results of MetaboAnalyst were based on the analysis with R version 3.0.3. Other statistical analyses 
were based on the Stata (version 13; Stata Corp, College Station, TX, USA) or R (version 3.1.3).
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